These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 30732170)

  • 21. Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.
    Camilleri E; Ghobreyal M; Bos MHA; Reitsma PH; Van Der Meer FJM; Swen JJ; Cannegieter SC; van Rein N
    Pharmacotherapy; 2024 Jun; 44(6):416-424. PubMed ID: 38686648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
    Ivashchenko D; Rusin I; Sychev D; Grachev A
    Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A global perspective on mechanical prosthetic heart valve thrombosis: Diagnostic and therapeutic challenges.
    Gürsoy MO; Kalçık M; Yesin M; Karakoyun S; Bayam E; Gündüz S; Özkan M
    Anatol J Cardiol; 2016 Dec; 16(12):980-989. PubMed ID: 28005024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prosthetic Heart Valve Thrombosis.
    Dangas GD; Weitz JI; Giustino G; Makkar R; Mehran R
    J Am Coll Cardiol; 2016 Dec; 68(24):2670-2689. PubMed ID: 27978952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves.
    Kalpana SR; Bharath G; Manjunath CN; Christopher R
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):876-882. PubMed ID: 27335128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients.
    Zhuang W; Wen W; Xuan B; Chen Y; Cao Y; Sun Z; Ma J
    Blood Coagul Fibrinolysis; 2015 Mar; 26(2):167-74. PubMed ID: 25304014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential inherited causes of recurrent prosthetic mitral valve thrombosis in a pregnant patient suffering from recurrent miscarriage.
    Kalcik M; Gursoy MO; Karakoyun S; Yesin M; Astarcioglu MA; Ozkan M
    Korean Circ J; 2014 Jul; 44(4):268-70. PubMed ID: 25089140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP4F2 1347 G > A & GGCX 12970 C > G polymorphisms: frequency in north Indians & their effect on dosing of acenocoumarol oral anticoagulant.
    Rathore SS; Agarwal SK; Pande S; Singh SK; Mittal T; Mittal B
    Indian J Med Res; 2014 Apr; 139(4):572-8. PubMed ID: 24927344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of anticardiolipin antibodies in the pathogenesis of prosthetic valve thrombosis: An observational study.
    Aykan AÇ; Gökdeniz T; Kalçık M; Astarcıoğlu MA; Gündüz S; Karakoyun S; Gürsoy MO; Oğuz AE; Ertürk E; Çakal B; Bayram Z; Özkan M
    Herz; 2015 May; 40(3):528-33. PubMed ID: 24441396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of obstructive thrombosed prosthetic heart valve.
    Huang G; Schaff HV; Sundt TM; Rahimtoola SH
    J Am Coll Cardiol; 2013 Nov; 62(19):1731-6. PubMed ID: 23994405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel associations of VKORC1 variants with higher acenocoumarol requirements.
    Anton AI; Cerezo-Manchado JJ; Padilla J; Perez-Andreu V; Corral J; Vicente V; Roldan V; Gonzalez-Conejero R
    PLoS One; 2013; 8(5):e64469. PubMed ID: 23691226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.
    Danese E; Montagnana M; Johnson JA; Rettie AE; Zambon CF; Lubitz SA; Suarez-Kurtz G; Cavallari LH; Zhao L; Huang M; Nakamura Y; Mushiroda T; Kringen MK; Borgiani P; Ciccacci C; Au NT; Langaee T; Siguret V; Loriot MA; Sagreiya H; Altman RB; Shahin MH; Scott SA; Khalifa SI; Chowbay B; Suriapranata IM; Teichert M; Stricker BH; Taljaard M; Botton MR; Zhang JE; Pirmohamed M; Zhang X; Carlquist JF; Horne BD; Lee MT; Pengo V; Guidi GC; Minuz P; Fava C
    Clin Pharmacol Ther; 2012 Dec; 92(6):746-56. PubMed ID: 23132553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.
    Fung E; Patsopoulos NA; Belknap SM; O'Rourke DJ; Robb JF; Anderson JL; Shworak NW; Moore JH
    Semin Thromb Hemost; 2012 Nov; 38(8):893-904. PubMed ID: 23041981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
    Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
    Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
    Takeuchi F; McGinnis R; Bourgeois S; Barnes C; Eriksson N; Soranzo N; Whittaker P; Ranganath V; Kumanduri V; McLaren W; Holm L; Lindh J; Rane A; Wadelius M; Deloukas P
    PLoS Genet; 2009 Mar; 5(3):e1000433. PubMed ID: 19300499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.
    Borgiani P; Ciccacci C; Forte V; Sirianni E; Novelli L; Bramanti P; Novelli G
    Pharmacogenomics; 2009 Feb; 10(2):261-6. PubMed ID: 19207028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
    Bonow RO; Carabello BA; Chatterjee K; de Leon AC; Faxon DP; Freed MD; Gaasch WH; Lytle BW; Nishimura RA; O'Gara PT; O'Rourke RA; Otto CM; Shah PM; Shanewise JS;
    J Am Coll Cardiol; 2008 Sep; 52(13):e1-142. PubMed ID: 18848134
    [No Abstract]   [Full Text] [Related]  

  • 38. CYP4F2 genetic variant alters required warfarin dose.
    Caldwell MD; Awad T; Johnson JA; Gage BF; Falkowski M; Gardina P; Hubbard J; Turpaz Y; Langaee TY; Eby C; King CR; Brower A; Schmelzer JR; Glurich I; Vidaillet HJ; Yale SH; Qi Zhang K; Berg RL; Burmester JK
    Blood; 2008 Apr; 111(8):4106-12. PubMed ID: 18250228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prosthetic valve thrombosis - association of genetic polymorphisms of VKORC1, CYP2C9 and CYP4F2 genes.
    Sr K; G B; Jain S; Moorthy N; Manjunath SC; Christopher R
    Medicine (Baltimore); 2019 Feb; 98(6):e14365. PubMed ID: 30732170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis.
    Zhang J; Chen Z; Chen C
    Meta Gene; 2016 Sep; 9():197-209. PubMed ID: 27617219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.